<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An. bras. dermatol.</journal-id>
      <journal-title-group>
        <journal-title>Anais brasileiros de dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23539016</article-id>
      <article-id pub-id-type="pmc">3699950</article-id>
      <article-id pub-id-type="doi">10.1590/S0365-05962013000100018</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Toxic epidermal necrolysis induced by lansoprazole<sup><xref ref-type="fn" rid="fn01">*</xref></sup></article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Necr&#xF3;lise epid&#xE9;rmica t&#xF3;xica induzida pelo lansoprazol</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Fracaroli</surname>
            <given-names>Tain&#xE1; Scalfoni</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miranda</surname>
            <given-names>Ludmilla Queir&#xF3;s</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sodr&#xE9;</surname>
            <given-names>Jo&#xE3;o Luz</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chaves</surname>
            <given-names>M&#xE1;rio</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gripp</surname>
            <given-names>Alexandre</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label> MD &#x2013; Graduate student in Dermatology at the Teaching Hospital, State University of Rio de Janeiro (Hospital Universit&#xE1;rio Pedro Ernesto &#x2013; Universidade do Estado do Rio de Janeiro - HUPE-UERJ) &#x2013; Rio de Janeiro (RJ), Brazil.
</aff>
      <aff id="aff2"><label>2</label> Resident in Dermatology at the Teaching Hospital, State University of Rio de Janeiro (Hospital Universit&#xE1;rio Pedro Ernesto &#x2013; Universidade do Estado do Rio de Janeiro - HUPE-UERJ) &#x2013; Rio de Janeiro (RJ), Brazil.
</aff>
      <aff id="aff3"><label>3</label> MD &#x2013; Dermatologist and research assistant at the Dermatology Service, Teaching Hospital, State University of Rio de Janeiro (Hospital Universit&#xE1;rio Pedro Ernesto &#x2013; Universidade do Estado do Rio de Janeiro - HUPE-UERJ) &#x2013; Rio de Janeiro (RJ), Brazil.
</aff>
      <aff id="aff4"><label>4</label> MD - Master's degree in Dermatology &#x2013; Assistant Professor in Dermatology and responsible for the Dermatology Infirmary at the Teaching Hospital, State University of Rio de Janeiro (Hospital Universit&#xE1;rio Pedro Ernesto &#x2013; Universidade do Estado do Rio de Janeiro - HUPE-UERJ) &#x2013; Rio de Janeiro (RJ), Brazil.
</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Tain&#xE2; Scalfoni Fracaroli Avenida 28 de Setembro, 77 Vila Isabel 20551030 Rio de Janeiro, RJ E-mail: <email>tsfracaroli@yahoo.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Jan-Feb</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>1</issue>
      <fpage>117</fpage>
      <lpage>120</lpage>
      <ext-link ext-link-type="uri" xlink:href="http://www.anaisdedermatologia.org.br">http://www.anaisdedermatologia.org.br</ext-link>
      <ext-link ext-link-type="uri" xlink:href="http://www.scielo.br/abd">http://www.scielo.br/abd</ext-link>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>11</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>1</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Toxic epidermal necrolysis is a rare, severe cutaneous reaction, mostly caused by drugs. It affects the skin and mucous membranes, with involvement of more than 30% of body surface. We describe the case of a young woman, previously healthy, who developed skin detachment of more than 90% of the body surface 15 days after being administered lansoprazole for peptic disease. The treatment consisted in discontinuation of the drug involved and early administration of intravenous human immunoglobulin, which led to a satisfactory outcome of the case, substantiating the impact of early diagnosis and treatment on the morbidity and mortality of these patients.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>A Necr&#xF3;lise epid&#xE9;rmica t&#xF3;xica &#xE9; uma rea&#xE7;&#xE3;o cut&#xE2;nea rara, causada principalmente por drogas. Envolve pele e mucosas, com acometimento superior a 30% da superf&#xED;cie corp&#xF3;rea. Ilustramos um caso de uma paciente jovem, previamente h&#xED;gida que desenvolveu necr&#xF3;lise epid&#xE9;rmica t&#xF3;xica, com descolamento superior a 90% da superf&#xED;cie corp&#xF3;rea, 15 dias ap&#xF3;s o in&#xED;cio de lanzoprazol para doen&#xE7;a p&#xE9;ptica. O tratamento consistiu na interrup&#xE7;&#xE3;o do uso da droga implicada e administra&#xE7;&#xE3;o precoce de imunoglobulina humana por via venosa, que levou a um desfecho satisfat&#xF3;rio do caso, demonstrando o impacto do diagn&#xF3;stico e tratamento precoces sobre a morbimortalidade destes pacientes.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Epidermal necrolysis, toxic</kwd>
        <kwd>Immunoglobulins, intravenous</kwd>
        <kwd>Proton pump inhibitors</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>Toxic epidermal necrolysis (TEN) is a rare disorder, having significant morbidity and over 30%. mortality<sup><xref ref-type="bibr" rid="r01">1</xref></sup> It is characterized by extensive apoptosis of keratinocytes, leading to epidermal detachment and mucosal involvement.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>The Stevens-Johnson syndrome (SJS) and TEN represent severe variants of the same process, due to etiopathogenic, clinical and histopathological similarities. These entities differ only in the percentage of body surface involved: a detachment below 10% represents SJS, 10-30% overlapping of both and above 30% it characterizes TEN.<sup><xref ref-type="bibr" rid="r03">3</xref></sup>
</p>
      <p>The main factors involved in the etiology are drugs, mainly antibiotics, anticonvulsants, oxicam family of nonsteroidal anti-inflammatory drugs and allopurinol. The proton pump inhibitors (lansoprazole and omeprazole) are considered of low risk.<sup><xref ref-type="bibr" rid="r04">4</xref>-<xref ref-type="bibr" rid="r06">6</xref></sup> Cases of TEN have been attributed to several new drugs, given that the ones with longer half-life pose higher risk. </p>
      <p>The pathogenesis is not fully understood and involves the inability to detoxicate reactive metabolites of drugs, genetic susceptibility and immune factors related to cellular apoptosis. The main pathway of cell death in this case is the interaction of Fas receptor and Fas ligand on the surface of the keratinocyte, since the latter acquires an increased expression on the surface of keratinocytes in TEN.<sup><xref ref-type="bibr" rid="r07">7</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>The clinical signs begins, on average, one week after administration of the drug, and it may range from 7 to 21 days in a first exposure. In a reexposure, the onset happens earlier, and it may happen in 2 days.<sup><xref ref-type="bibr" rid="r02">2</xref>,<xref ref-type="bibr" rid="r04">4</xref></sup> It is common that unspecific symptoms such as fever, sore throat, stinging eyes and vagina, precede cutaneous manifestations by a few days. The first lesions tend to happen on the trunk, and are usually erythematous papules or purpuric macules, irregular in shape and size, which tend to coalesce. The progression of the disease, if the offending drug is not removed, occurs from 2 to 5 days or in hours; it rarely takes more than one week. The lesions become greyish red, there is intense necrosis of the whole epidermis, and flaccid blisters are formed, leaving large denuded areas. There is oral mucosa, ocular and genital involvement in more than 90% of the patients with extensive and painful erosions which lead to lip crusts, odynophagia, photophobia, dysuria and painful evacuations.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup> Systemic manifestations happen due to acute cutaneous failure, which results in water and electrolytic disorder, hypovolemia, renal failure, thermoregulatory unbalance and higher predisposition to sepsis.<sup><xref ref-type="bibr" rid="r01">1</xref></sup>
</p>
      <p>There is a severity score for TEN (SCORTEN), which may be useful to assess the prognosis of these patients, if performed within the first 48 hours of onset (<xref ref-type="table" rid="t01">Table 1</xref>).<sup><xref ref-type="bibr" rid="r07">7</xref></sup> Factors such as lymphadenopathy, increased transaminasis and neutropenia also imply worse prognosis.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup> Management in the acute stage involves prompt identification and withdrawal of the culprit drug, support therapy in intensive care unit or burn intensive care and eventual specific drug therapy. Early ophthalmologic evaluation is important to avoid late complications, such as synechia and amaurosis.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r09">9</xref></sup>
</p>
      <table-wrap id="t01" orientation="portrait" position="float">
        <label>Table 1</label>
        <caption>
          <p>Score of severity of TEN - SCORTEN</p>
        </caption>
        <table frame="hsides" rules="groups">
          <thead>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>Prognostic factors</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Points</bold>
              </td>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td rowspan="1" colspan="1">Age &gt; 40 years</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Tachycardia &gt; 120 bpm</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Neoplasia</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Initial detachment &gt; 10%</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serum urea &gt; 10 mmol/L</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Serum bicarbonate &lt; 20mmol/L</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">Blood glucose &gt; 14 mmol/L</td>
              <td rowspan="1" colspan="1">1</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#xA0;</td>
              <td rowspan="1" colspan="1">&#xA0;</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">
                <bold>SCORTEN</bold>
              </td>
              <td rowspan="1" colspan="1">
                <bold>Mortality (%)</bold>
              </td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">0-1</td>
              <td rowspan="1" colspan="1">3</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">2</td>
              <td rowspan="1" colspan="1">12</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">3</td>
              <td rowspan="1" colspan="1">35</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">4</td>
              <td rowspan="1" colspan="1">58</td>
            </tr>
            <tr>
              <td rowspan="1" colspan="1">&#x2265; 5</td>
              <td rowspan="1" colspan="1">90</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Systemic corticosteroids were the main therapy over decades. Currently, their use is controversial, some experts suggest there is increased risk of sepsis and death, while others show that short course of high dose, at the onset, may be beneficial.<sup><xref ref-type="bibr" rid="r09">9</xref> ,<xref ref-type="bibr" rid="r10">10</xref></sup> The administration of high doses of intravenous immunoglobulin (IVIG) seems to be a promising alternative, as it showed reduction in mortality in some studies. Its probable mechanism of action consists in blocking the Fas receptor-Fas ligand binding, thus inhibiting the apoptosis of keratinocytes. The dose has not been established yet, but the literature shows a higher benefit with the early administration of high doses (2-3 g/kg divided in 3-4 days).<sup><xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r09">9</xref>,<xref ref-type="bibr" rid="r10">10</xref></sup> Other drugs may be used, such as cyclosporine, cyclophosphamide and TNF-alpha antagonists.<sup><xref ref-type="bibr" rid="r04">4</xref>,<xref ref-type="bibr" rid="r07">7</xref></sup>
</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A previously healthy, 23-year-old woman, began to have ocular and vaginal itching and later symmetrical erythematous macules appeared on the limbs, mainly hands and feet. Within 7 days there was significant spread of lesions, which evolved into blisters. She sought the emergency care unit, where prednisone 2 mg/kg was administered. After 2 days, she was transferred to our service. She reported use of lansoprazole 15 days before the appearance of the lesions. </p>
      <p>On examination, the patient was pale 2+/ 4 + , febrile and tachycardic. Epidermal detachment involved more than 90% of the body surface, and there were some areas of erosion (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>). Mild involvement of the oral mucosa and lips with crust formation. She was admitted to the intensive care unit, lansoprazole was stopped and intravenous immunoglobulin, 2 g/kg was administered for 3 days, in addition to skin debridement and daily dressings. The patient developed significant reepithelialization in 15 days (<xref ref-type="fig" rid="f03">Figures 3</xref> and <xref ref-type="fig" rid="f04">4</xref>). After two months, she presents only residual hyperchromic macules. </p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Extensive epidermal detachment</p>
        </caption>
        <graphic xlink:href="abd-88-0117-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Erosion in areas of more pressure</p>
        </caption>
        <graphic xlink:href="abd-88-0117-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Evolution: 15 days after admission</p>
        </caption>
        <graphic xlink:href="abd-88-0117-g03"/>
      </fig>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Progressive reepithelization</p>
        </caption>
        <graphic xlink:href="abd-88-0117-g04"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>The proton pump inhibitors are drugs which are little related to the development of TEN, and only 5 cases have been reported in the literature to date. Nonetheless, as they are often used, they may not be considered as cause of pharmacodermia. Our patient showed symptoms 15 days after the administration of lansoprazole and had nonspecific complaints 1 day before the onset of skin lesions, as described in the literature. However, the first lesions were on the extremities and there was palmoplantar involvement, which is not frequent. Although the patient has presented more than 90% of epidermal detachment, there were no severe systemic complications, and the process ended after withdrawal of the culprit drug and immunoglobulin administration. </p>
      <p>We believe that SCORTEN is useful, but in this case it was not used because the patient was admitted nine days after onset of symptoms. Early ophthalmologic evaluation and daily eye care were performed, as ocular synechia is the main long-term sequela. Due to the involvement of the skin and mucous membranes (oral, ocular and genital), an interdisciplinary assessment is important. </p>
      <p>The diagnosis is clinical and must not be delayed due to high mortality. It is hard to establish a therapy of choice for TEN, due to the rarity of the disorder and the difficulty of performing controlled clinical trials, but intravenous immunoglobulin is a promising therapeutic option, as there is evidence it may stop the necrosis process. </p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="financial-disclosure">
        <p>Financial support: none.</p>
      </fn>
      <fn fn-type="conflict">
        <p>Conflict of interests: none.</p>
      </fn>
      <fn id="fn01" fn-type="other">
        <p>* Study carried out at the Teaching Hospital, State University of Rio de Janeiro (Hospital Universit&#xE1;rio Pedro Ernesto - Universidade do Estado do Rio de Janeiro - HUPE - UERJ) - Rio de Janeiro (RJ), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roujeau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Guillaume</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Fabre</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Penso</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Fl&#xE9;chet</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Girre</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Toxic epidermal necrolysis (Lyell Syndrome). Incidence and drug aetiology in France, 1981-85</article-title>
          <source>Arch Dermatol</source>
          <year>1990</year>
          <volume>126</volume>
          <fpage>37</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="pmid">2134982</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bastuji-Garin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rzany</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stern</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Shear</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Naldi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Roujeau</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme</article-title>
          <source>Arch Dermatol</source>
          <year>1993</year>
          <volume>129</volume>
          <fpage>92</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">8420497</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Criado</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>Criado</surname>
              <given-names>RFJ</given-names>
            </name>
            <name>
              <surname>Vasconcellos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ramos</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Gon&#xE7;alves</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Rea&#xE7;&#xF5;es cut&#xE2;neas graves adversas a drogas - aspectos relevantes ao diagn&#xF3;stico e ao tratamento - Parte I - Anafilaxia e rea&#xE7;&#xF5;es anafilact&#xF3;ides, eritrodermias e o espectro cl&#xED;nico da s&#xED;ndrome de Stevens-Johnson &amp; necr&#xF3;lise epid&#xE9;rmica t&#xF3;xica (Doen&#xE7;a de Lyell)</article-title>
          <source>An Bras Dermatol</source>
          <year>2004</year>
          <volume>79</volume>
          <fpage>471</fpage>
          <lpage>88</lpage>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pereira</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Mudgil</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Rosmarin</surname>
              <given-names>DM</given-names>
            </name>
          </person-group>
          <article-title>Toxic epidermal necrolysis</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>181</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">17224365</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thakor</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Burke</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Handfield-Jones</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sinha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Palmer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Burns</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Toxic epidermal necrolysis and neutropaenia: complications of omeprazole</article-title>
          <source>Aust J Dermatol</source>
          <year>2009</year>
          <volume>50</volume>
          <fpage>207</fpage>
          <lpage>10</lpage>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heaton</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Edmonds</surname>
              <given-names>EV</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Bunker</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Bowling</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Morar</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Fatal toxic epidermal necrolysis due to lansoprazole</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2004</year>
          <volume>29</volume>
          <fpage>612</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">15550134</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rajaratnam</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Balasubramaniam</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Marsden</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Taibjee</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>F</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre</article-title>
          <source>Clin Exp Dermatol</source>
          <year>2010</year>
          <volume>35</volume>
          <fpage>853</fpage>
          <lpage>862</lpage>
          <pub-id pub-id-type="pmid">20456393</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marzano</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Frezzolini</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Caproni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Parodi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Fanoni</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Quaglino</surname>
              <given-names>P</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis</article-title>
          <source>Int J Immunopathol Pharmacol</source>
          <year>2007</year>
          <volume>20</volume>
          <fpage>557</fpage>
          <lpage>66</lpage>
          <pub-id pub-id-type="pmid">17880768</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chave</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Mortimer</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Sladden</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Hutchinson</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>Toxic epidermal necrolysis: current evidence, practical management and future directions</article-title>
          <source>Br J Dermatol</source>
          <year>2005</year>
          <volume>153</volume>
          <fpage>241</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="pmid">16086734</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schneck</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fagot</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Sekula</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sassolas</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Roujeau</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Mockenhaupt</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2008</year>
          <volume>58</volume>
          <fpage>33</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">17919775</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
